448 related articles for article (PubMed ID: 29255415)
21. Evaluation of clinical efficacy of fasudil for the treatment of pulmonary arterial hypertension.
Raja SG
Recent Pat Cardiovasc Drug Discov; 2012 Aug; 7(2):100-4. PubMed ID: 22670803
[TBL] [Abstract][Full Text] [Related]
22. Soluble Guanylate Cyclase Stimulators and Activators: Novel Therapies for Pulmonary Vascular Disease or a Different Method of Increasing cGMP?
Koress C; Swan K; Kadowitz P
Curr Hypertens Rep; 2016 Apr; 18(5):42. PubMed ID: 27118316
[TBL] [Abstract][Full Text] [Related]
23. [Novel concepts in the pathobiology of pulmonary arterial hypertension].
Rosenkranz S
Dtsch Med Wochenschr; 2008 Oct; 133 Suppl 6():S167-9. PubMed ID: 18814087
[TBL] [Abstract][Full Text] [Related]
24. BMP type II receptor as a therapeutic target in pulmonary arterial hypertension.
Orriols M; Gomez-Puerto MC; Ten Dijke P
Cell Mol Life Sci; 2017 Aug; 74(16):2979-2995. PubMed ID: 28447104
[TBL] [Abstract][Full Text] [Related]
25. Soluble guanylate cyclase stimulators in pulmonary hypertension.
Stasch JP; Evgenov OV
Handb Exp Pharmacol; 2013; 218():279-313. PubMed ID: 24092345
[TBL] [Abstract][Full Text] [Related]
26. Current treatment options in children with pulmonary arterial hypertension and experiences with oral bosentan.
Beghetti M
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():16-24. PubMed ID: 16919006
[TBL] [Abstract][Full Text] [Related]
27. [Update: Preclinical developments for the treatment of pulmonary arterial hypertension].
Janssen W; Ghofrani HA; Weissmann N; Grimminger F; Schermuly RT
Dtsch Med Wochenschr; 2009 Aug; 134 Suppl 5():S157-9. PubMed ID: 19718604
[TBL] [Abstract][Full Text] [Related]
28. Development of occlusive neointimal lesions in distal pulmonary arteries of endothelin B receptor-deficient rats: a new model of severe pulmonary arterial hypertension.
Ivy DD; McMurtry IF; Colvin K; Imamura M; Oka M; Lee DS; Gebb S; Jones PL
Circulation; 2005 Jun; 111(22):2988-96. PubMed ID: 15927975
[TBL] [Abstract][Full Text] [Related]
29. Nebivolol for improving endothelial dysfunction, pulmonary vascular remodeling, and right heart function in pulmonary hypertension.
Perros F; Ranchoux B; Izikki M; Bentebbal S; Happé C; Antigny F; Jourdon P; Dorfmüller P; Lecerf F; Fadel E; Simonneau G; Humbert M; Bogaard HJ; Eddahibi S
J Am Coll Cardiol; 2015 Feb; 65(7):668-80. PubMed ID: 25677428
[TBL] [Abstract][Full Text] [Related]
30. Endothelial nitric oxide synthase-enhancing G-protein coupled receptor antagonist inhibits pulmonary artery hypertension by endothelin-1-dependent and endothelin-1-independent pathways in a monocrotaline model.
Liu CP; Dai ZK; Huang CH; Yeh JL; Wu BN; Wu JR; Chen IJ
Kaohsiung J Med Sci; 2014 Jun; 30(6):267-78. PubMed ID: 24835346
[TBL] [Abstract][Full Text] [Related]
31. Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy.
Schermuly RT; Pullamsetti SS; Kwapiszewska G; Dumitrascu R; Tian X; Weissmann N; Ghofrani HA; Kaulen C; Dunkern T; Schudt C; Voswinckel R; Zhou J; Samidurai A; Klepetko W; Paddenberg R; Kummer W; Seeger W; Grimminger F
Circulation; 2007 May; 115(17):2331-9. PubMed ID: 17438150
[TBL] [Abstract][Full Text] [Related]
32. Endothelin receptor antagonism in pulmonary arterial hypertension--a role for selective ET(A) inhibition?
Jacobs A; Preston IR; Gomberg-Maitland M
Curr Med Res Opin; 2006 Dec; 22(12):2567-74. PubMed ID: 17166339
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological Inhibition of mTOR Kinase Reverses Right Ventricle Remodeling and Improves Right Ventricle Structure and Function in Rats.
Pena A; Kobir A; Goncharov D; Goda A; Kudryashova TV; Ray A; Vanderpool R; Baust J; Chang B; Mora AL; Gorcsan J; Goncharova EA
Am J Respir Cell Mol Biol; 2017 Nov; 57(5):615-625. PubMed ID: 28679058
[TBL] [Abstract][Full Text] [Related]
34. Molecular mechanisms of right ventricular dysfunction in pulmonary arterial hypertension: focus on the coronary vasculature, sex hormones, and glucose/lipid metabolism.
Agrawal V; Lahm T; Hansmann G; Hemnes AR
Cardiovasc Diagn Ther; 2020 Oct; 10(5):1522-1540. PubMed ID: 33224772
[TBL] [Abstract][Full Text] [Related]
35. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension.
Schermuly RT; Stasch JP; Pullamsetti SS; Middendorff R; Müller D; Schlüter KD; Dingendorf A; Hackemack S; Kolosionek E; Kaulen C; Dumitrascu R; Weissmann N; Mittendorf J; Klepetko W; Seeger W; Ghofrani HA; Grimminger F
Eur Respir J; 2008 Oct; 32(4):881-91. PubMed ID: 18550612
[TBL] [Abstract][Full Text] [Related]
36. Steps forward in the treatment of pulmonary arterial hypertension: latest developments and clinical opportunities.
Badlam JB; Bull TM
Ther Adv Chronic Dis; 2017 Feb; 8(2-3):47-64. PubMed ID: 28348727
[TBL] [Abstract][Full Text] [Related]
37. Cellular and molecular pathobiology of pulmonary arterial hypertension.
Humbert M; Morrell NW; Archer SL; Stenmark KR; MacLean MR; Lang IM; Christman BW; Weir EK; Eickelberg O; Voelkel NF; Rabinovitch M
J Am Coll Cardiol; 2004 Jun; 43(12 Suppl S):13S-24S. PubMed ID: 15194174
[TBL] [Abstract][Full Text] [Related]
38. Absence of the Adenosine A2A Receptor Confers Pulmonary Arterial Hypertension Through RhoA/ROCK Signaling Pathway in Mice.
Shang P; He ZY; Chen JF; Huang SY; Liu BH; Liu HX; Wang XT
J Cardiovasc Pharmacol; 2015 Dec; 66(6):569-75. PubMed ID: 26647014
[TBL] [Abstract][Full Text] [Related]
39. Neurohormonal activation and pharmacological inhibition in pulmonary arterial hypertension and related right ventricular failure.
Ameri P; Bertero E; Meliota G; Cheli M; Canepa M; Brunelli C; Balbi M
Heart Fail Rev; 2016 Sep; 21(5):539-47. PubMed ID: 27206576
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
